Semaglutide for PCOS and insulin resistance: what the evidence says

What did @shayystewart actually say?

Two days after her second weekly injection of compounded semaglutide at the 0.25mg starting dose, @shayystewart walked through her side effect experience and the habits she's stacking alongside it. She reported nausea and "really bad migraines" in week one, with fatigue lingering into week two. She credits switching to a nighttime injection with reducing those early symptoms. She also claims semaglutide helps your body "use your fat stores instead of just relying on eating all the time," and suspects the B12 her compounded formulation includes is responsible for a noticeable boost in gym energy. She's prioritizing protein and intentional daily movement.

Does the science back this up?

Mostly, yes, with one significant caveat about the B12 energy claim. The side effect profile she describes is well-documented, and the nighttime injection tip has real logic behind it. Her fat metabolism explanation is loosely accurate but oversimplified.

Nausea and headache are among the most commonly reported early adverse effects with semaglutide. In the SUSTAIN and STEP trial series, gastrointestinal side effects occurred in 40-44% of participants, predominantly in the titration phase (Wilding et al., 2021, NEJM). Fatigue is less formally tracked but consistent with anecdotal and clinical reports during dose initiation.

The nighttime injection strategy is not in any prescribing label, but the reasoning is pharmacologically sound. Semaglutide reaches peak plasma concentration roughly 24-72 hours after subcutaneous injection (Kapitza et al., 2012, Clinical Pharmacokinetics), so sleeping through part of that window may genuinely reduce perceived side effect intensity. It is not a studied protocol, but it is not pseudoscience either.

Her fat metabolism comment, "your body's able to actually use your fat stores," is a rough but not entirely wrong description of how GLP-1 receptor agonists work in the context of insulin regulation. In people with insulin resistance, which she references and which is common in PCOS, improved insulin sensitivity can shift the body toward fat oxidation. But this is a slow metabolic effect, not a direct mechanism of the drug itself.

What did they get wrong (or right)?

The B12-energy claim is the shakiest part of this video. She says, "I don't know if that's the B12 that my semaglutide's compounded with, but probably." That is a reasonable guess, but the evidence does not strongly support it in people who are not B12-deficient. A 2019 Cochrane review found no consistent evidence that B12 supplementation improves energy or reduces fatigue in people with normal B12 levels (Martens et al., 2019, Cochrane Database). If she has low B12, which is more common in people with PCOS and insulin resistance treated with metformin, then yes, repletion could help. But she does not mention a deficiency, and attributing gym energy gains to added B12 in a compounded peptide is speculative at best.

She also says the sparkling drinks have "70 grams of caffeine," clearly meaning milligrams. Small error, does not affect the health content.

What she got right: protein prioritization during GLP-1 therapy is clinically supported. Because semaglutide suppresses appetite broadly, inadequate protein intake is a real risk, and higher protein diets help preserve lean muscle mass during weight loss (Leidy et al., 2015, American Journal of Clinical Nutrition).

What should you actually know?

A few things this video glosses over are worth naming directly. First, compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. The FDA has flagged concerns about compounded versions, including inconsistent dosing and the use of semaglutide salt forms not found in approved products. Assuming they are interchangeable is not accurate.

Second, the headache and migraine symptoms she describes should not just be pushed through with hydration alone. Severe or persistent headaches during GLP-1 initiation can reflect dehydration-driven electrolyte shifts and deserve a clinical check-in, not just more water.

Third, PCOS is mentioned throughout but the video does not address whether semaglutide is specifically indicated for her situation. While there is growing evidence that GLP-1 receptor agonists improve metabolic and hormonal markers in PCOS, including insulin resistance and androgen levels (Jensterle et al., 2022, Frontiers in Endocrinology), this is still an off-label use, and outcomes vary based on the individual's hormonal profile.

Her commitment to protein and daily movement is genuinely good practice. The lifestyle framing around having kids and changing habits is relatable, but viewers with PCOS should work with a provider who is monitoring their labs, not just their weight.